The pharmaceutical giant Bayer has made a remarkable—and lucrative—discovery. Allergies are on the rise. The company’s eye and nose ointment Bepanthen, already good for more than $200 million in annual sales, could soon be in even higher demand. Bayer mentions this in its annual response to the watchdog CDP, formerly the Carbon Disclosure Project, which surveys the greenhouse gas emissions of the world’s largest corporations. The CDP celebrates companies that cut carbon, of course, but also celebrates brutal honesty, awarding prizes and A rankings to those that give a true and full accounting of how climate change could affect their bottom lines. Bayer is a winner on both counts. Though still high, its emissions are down nearly 40% from 1990 levels. And the company is transparent about what it believes a warming world will bring.
The Big Business of Global Warming
The Big Business of Global Warming
The Big Business of Global Warming
The pharmaceutical giant Bayer has made a remarkable—and lucrative—discovery. Allergies are on the rise. The company’s eye and nose ointment Bepanthen, already good for more than $200 million in annual sales, could soon be in even higher demand. Bayer mentions this in its annual response to the watchdog CDP, formerly the Carbon Disclosure Project, which surveys the greenhouse gas emissions of the world’s largest corporations. The CDP celebrates companies that cut carbon, of course, but also celebrates brutal honesty, awarding prizes and A rankings to those that give a true and full accounting of how climate change could affect their bottom lines. Bayer is a winner on both counts. Though still high, its emissions are down nearly 40% from 1990 levels. And the company is transparent about what it believes a warming world will bring.